Xenetic Biosciences Inc
NASDAQ:XBIO
Intrinsic Value
Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant... [ Read More ]
The intrinsic value of one
XBIO
stock under the Base Case scenario is
10.07
USD.
Compared to the current market price of 4.09 USD,
Xenetic Biosciences Inc
is
Undervalued by 59%.
Xenetic Biosciences Inc's market capitalization is 6.3m USD.
XBIO stock price is 4.09 USD.
XBIO stock price (4.09 USD) is 59% less than its Intrinsic Value (10.07 USD).
XBIO. Open DCF Valuation
XBIO stock price (4.09 USD) is 59% less than its Relative Value (10.07 USD). Open Relative Valuation
XBIO.
XBIO's Revenue is forecast to fall at a rate of 3% per year over the next 3 years.
XBIO's Revenue has grown by an exceptional 49% over the past 12 months.
XBIO's ROE (Return on Equity) has significantly increased in the last 3 years from -81% to -35%, and is approaching profitability.
XBIO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -239% to -333%, and is approaching profitability.
XBIO has negative Operating Income for the last twelve months.
XBIO has negative Net Income for the last twelve months.
XBIO's ROE (Return on Equity) for the past 12 months is negative and is equal to -35%.
XBIO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -333%.
XBIO has negative Free Cash Flow for the last twelve months.
XBIO's Revenue has been growing by an exceptional 79% per year for the last 3 years.
XBIO has negative three-year average ROE (Return on Equity): -49%. The company is not efficient at transforming stockholders' equity into net income.
XBIO has negative three-year average ROIC (Return on Invested Capital): -365%. The company is not efficient at using invested capital to generate operating income.
XBIO's short-term assets (10m USD) exceed its short-term liabilties (810k USD).
XBIO's long-term assets (11m USD) exceed its long-term liabilties (810k USD).
XBIO's D/E (Debt to Equity) is very low and is equal to 0.
XBIO's Altman Z-Score is very low and is equal to -22.76.
Valuation Backtest
Xenetic Biosciences Inc
Run backtest to discover the historical profit from buying and selling
XBIO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Xenetic Biosciences Inc
Balance Sheet Decomposition
Xenetic Biosciences Inc
| Current Assets | 9.6m |
| Cash & Short-Term Investments | 9m |
| Other Current Assets | 603.8k |
| Non-Current Assets | 1m |
| Other Non-Current Assets | 1m |
| Current Liabilities | 809.6k |
| Accounts Payable | 240.8k |
| Accrued Liabilities | 568.8k |
| Other Current Liabilities | 10 |
Earnings Waterfall
Xenetic Biosciences Inc
|
Revenue
|
2.5m
USD
|
|
Operating Expenses
|
-7.1m
USD
|
|
Operating Income
|
-4.5m
USD
|
|
Other Expenses
|
381.1k
USD
|
|
Net Income
|
-4.1m
USD
|
Free Cash Flow Analysis
Xenetic Biosciences Inc
XBIO Profitability Score
Profitability Due Diligence
Xenetic Biosciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Xenetic Biosciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
XBIO Solvency Score
Solvency Due Diligence
Xenetic Biosciences Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Xenetic Biosciences Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XBIO Price Targets Summary
Xenetic Biosciences Inc
Shareholder Return
XBIO Price
Xenetic Biosciences Inc
| Average Annual Return | -38.19% |
| Standard Deviation of Annual Returns | 65.62% |
| Max Drawdown | -99% |
| Market Capitalization | 6.3m USD |
| Shares Outstanding | 1 540 680 |
| Percentage of Shares Shorted | 0.11% |
Company Profile
Xenetic Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The firm's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. The company uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.
Contact
IPO
Employees
Officers
The intrinsic value of one
XBIO
stock under the Base Case scenario is
10.07
USD.
Compared to the current market price of 4.09 USD,
Xenetic Biosciences Inc
is
Undervalued by 59%.
You don't have any saved screeners yet
